Clinical efficacy was proven in a multicenter, randomized phase III trial (ADMIRAL trial), that evaluated the benefit of gilteritinib monotherapy against a standard salvage chemotherapy of choice in 371 patients with r/r FLT3 mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.